Search Results - neurodegenerative+disease

28 Results Sort By:
The Use of Annexins in Preventing and Treating Muscle Membrane Injury
NU 2018-119 INVENTORS Elizabeth McNally* Alexis Demonbreun SHORT DESCRIPTION An annexin-based biological therapeutic that enhances the body's natural cell membrane repair process to reduce muscle cell death and preserve tissue function. BACKGROUND Cell membrane integrity is critical for survival, especially in tissues under constant mechanical...
Published: 12/9/2025   |   Inventor(s):  
Keywords(s): Neurodegenerative disease, Therapeutics
Category(s): Life Sciences > Therapeutics
Novel 2-Imidazolyl-Pyrimidine Inhibitors for Neurodegenerative Disease Therapeutics
NU 2014-101 INVENTORS Richard Silverman* Paramita Mukherjee SHORT DESCRIPTION This invention introduces novel 2-imidazolyl-pyrimidine scaffolds that inhibit neuronal nitric oxide synthase. It offers potential for drug development targeting Parkinson’s and other neurodegenerative diseases. BACKGROUND Neurodegenerative disorders such as...
Published: 12/3/2025   |   Inventor(s):  
Keywords(s): Biomedical, Materials, Neurodegenerative disease, Neurologic disease, Neurology, Small molecule, Therapeutics
Category(s): Physical Sciences > Materials and Industrial Processes
2-(Pyridin-3-yl)quinazoline compounds as glucocerebrosidase modulators
✅ Feedback form for Tech ID 2015-064 PROPOSED TITLE: 2-(Pyridin-3-yl) quinazoline Compounds as Glucocerebrosidase Modulators NU 2015-064 INVENTORS Richard Silverman* Dimitri Krainc Jianbin Zheng SHORT DESCRIPTION Novel substituted quinazoline compounds that modulate glucocerebrosidase activity, offering a promising therapeutic approach for...
Published: 11/18/2025   |   Inventor(s):  
Keywords(s): Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Research tool, Therapeutics
Category(s): Life Sciences > Therapeutics
Development of Therapeutics for Amyotrophic Lateral Sclerosis (ALS)
NU 2008-163 and NU2009-098 Inventors Richard B. Silverman* Richard Morimoto P. Hande Ozdinler Short Description Three series of New Chemical Entities (NCEs) that exhibit efficacy in an ALS animal model Background ALS causes muscle weakness and atrophy due to the degeneration of the upper and lower motor neurons. This disease is both genetic...
Published: 11/18/2025   |   Inventor(s):  
Keywords(s): Neurodegenerative disease, Neurologic disease, Therapeutics
Category(s): Life Sciences > Therapeutics
Pyrimidine-2,4,6-Trione Derivatives Preparation and Their Use for the Treatment of Amyotrophic Lateral Sclerosis (ALS) ALS Therapy
NU 2009-072 INVENTORS Richard Morimoto* Richard Silverman* Gavin Guoyao Xia SHORT DESCRIPTION This invention discloses novel pyrimidine-2,4,6-trione derivatives (PYT compounds) that prevent abnormal protein aggregation associated with ALS, offering a promising new therapeutic approach for neurodegenerative diseases. BACKGROUND Amyotrophic...
Published: 11/18/2025   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, Neurodegenerative disease, Therapeutics
Category(s): Life Sciences > Therapeutics
Potent and selective Cav1.3 negative allosteric modulators for use in Parkinson's Disease
NU 2010-105 and NU 2024-179 INVENTORS Richard Silverman* (Northwestern University, Weinberg College of Arts & Science, Department of Chemistry) Dalton Surmeier Jr.* (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience) Garry Cooper Soosung Kang Jack Nguyen SHORT DESCRIPTION For pharmaceutical...
Published: 11/11/2025   |   Inventor(s):  
Keywords(s): Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease
Category(s): Life Sciences > Therapeutics
A Novel Combination Therapy for Parkinson’s Disease
NU 2013-149 INVENTORS Dalton Surmeier Jr. (Northwestern University, Feinberg School of Medicine, Chair of the Department of Neuroscience)* Daniel Galtieri Ema Ilijic Enrico Zampese Jaime Guzman-Lucero Javier Sanchez SHORT DESCRIPTION This technology uses a low-dose combination of two FDA-approved compounds to reduce oxidative stress in neurons...
Published: 11/6/2025   |   Inventor(s):  
Keywords(s): Biomedical, Drug delivery, Neurodegenerative disease, Neurologic disease, PD - Parkinson's Disease, Therapeutics
Category(s): Life Sciences > Therapeutics
Cell-type specific disruption of M1 muscarinic acetylcholine receptor expression to alleviate Parkinson's disease
NU 2024-244 INVENTORS Dalton J. Surmeier Jr* Tatiana Tkatch Shenyu Zhai SHORT DESCRIPTION Gene therapy targeting M1 muscarinic receptor expression in striatal spiny projection neurons to enhance levodopa response and slow Parkinson’s Disease progression. BACKGROUND Parkinson’s Disease (PD) is the second most common age-related...
Published: 11/6/2025   |   Inventor(s):  
Keywords(s): CNS - Central Nervous System, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease
Category(s): Life Sciences > Therapeutics
Gene therapy for levodopa-induced dyskinesia
NU 2024-086 INVENTORS Dalton J. Surmeier Jr* Weixing Shen Shenyu Zhai Tatiana Tkatch Qiaoling Cui Zhong Xie SHORT DESCRIPTION Gene therapy targeting GRIN2B in striatal spiny projection neurons to treat levodopa-induced dyskinesia. BACKGROUND Parkinson’s Disease (PD) is the second most common age-related neurodegenerative disease...
Published: 11/6/2025   |   Inventor(s):  
Keywords(s): CNS - Central Nervous System, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease
Category(s): Life Sciences > Therapeutics
Therapeutic Intervention for ALS and Dementia
NU 2021-058 INVENTORS Evangelos Kiskinis* Juan Alberto Ortega Cano Marco Boccitto SHORT DESCRIPTION Design of an RNA-based oligonucleotide that protects from dipeptide repeat protein toxicity for the treatment of ALS and FTD. BACKGROUND Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases...
Published: 11/6/2025   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, CNS - Central Nervous System, DPR - Dipeptide Repeat Proteins, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurology, RNA - Ribonucleic Acid, Therapeutics
Category(s): Life Sciences > Therapeutics
1 2 3